Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
008 patients from 38 studies: 8805 in the PARPi group and 6203 in the control group.
I · Intervention 중재 / 시술
PARPi as monotherapy or in combination
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
our findings indicate a possible association between PARPi and VTE risk in certain cancer types, this risk appears to be influenced by factors such as cancer subtype and treatment combinations.
[BACKGROUND] Poly (ADP-ribose) polymerase inhibitors (PARPi) are linked to thrombotic events, but the thrombosis risk in various cancers is unclear.
- 표본수 (n) 4348
- p-value P = 0.050
- p-value P = 0.030
- 95% CI 1.06-3.70
- 연구 설계 meta-analysis
APA
Yazgan SC, Yekedüz E, et al. (2025). Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.. ESMO open, 10(10), 105811. https://doi.org/10.1016/j.esmoop.2025.105811
MLA
Yazgan SC, et al.. "Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis.." ESMO open, vol. 10, no. 10, 2025, pp. 105811.
PMID
41027069
Abstract
[BACKGROUND] Poly (ADP-ribose) polymerase inhibitors (PARPi) are linked to thrombotic events, but the thrombosis risk in various cancers is unclear. This study evaluates the incidence and risk of venous thromboembolic events (VTEs) in patients with solid tumors treated with PARPi.
[MATERIALS AND METHODS] This meta-analysis included randomized controlled phase II and III clinical trials in which patients with prostate, breast, ovarian, pancreatic, glioblastoma, small-cell lung (SCLC), and non-small-cell lung (NSCLC) cancers were treated with PARPi as monotherapy or in combination. The primary endpoint was to assess the frequency and risk of VTEs in patients treated with PARPi, while the secondary endpoint compared the incidence across different cancer subtypes.
[RESULTS] The analysis included 15 008 patients from 38 studies: 8805 in the PARPi group and 6203 in the control group. There were 11 ovarian cancer (n = 4348), 8 prostate cancer (n = 3872), 9 breast cancer (n = 4448), 4 NSCLC (n = 1063), and 3 SCLC (n = 583) studies, and 1 study each for pancreatic cancer (n = 50), glioblastoma (n = 123), and gastric (n = 521) cancer. The incidence of any-grade VTEs with PARPi was observed to be 2.4%, compared with 1.6% in controls, suggesting a possible increase in risk [odds ratio (OR) 1.37, 95% confidence interval (CI) 1.00-1.88, P = 0.050]. This association appeared to be more pronounced in patients with prostate cancer (OR 1.98, 95% CI 1.06-3.70, P = 0.030) and pancreatic cancer (OR 7.22, 95% CI 1.40-37.25, P = 0.020).
[CONCLUSIONS] While our findings indicate a possible association between PARPi and VTE risk in certain cancer types, this risk appears to be influenced by factors such as cancer subtype and treatment combinations. The overall contribution of PARPi monotherapy to VTE risk may be limited, and the results should be interpreted with caution due to study heterogeneity, wide CIs, and the absence of patient-level data.
[MATERIALS AND METHODS] This meta-analysis included randomized controlled phase II and III clinical trials in which patients with prostate, breast, ovarian, pancreatic, glioblastoma, small-cell lung (SCLC), and non-small-cell lung (NSCLC) cancers were treated with PARPi as monotherapy or in combination. The primary endpoint was to assess the frequency and risk of VTEs in patients treated with PARPi, while the secondary endpoint compared the incidence across different cancer subtypes.
[RESULTS] The analysis included 15 008 patients from 38 studies: 8805 in the PARPi group and 6203 in the control group. There were 11 ovarian cancer (n = 4348), 8 prostate cancer (n = 3872), 9 breast cancer (n = 4448), 4 NSCLC (n = 1063), and 3 SCLC (n = 583) studies, and 1 study each for pancreatic cancer (n = 50), glioblastoma (n = 123), and gastric (n = 521) cancer. The incidence of any-grade VTEs with PARPi was observed to be 2.4%, compared with 1.6% in controls, suggesting a possible increase in risk [odds ratio (OR) 1.37, 95% confidence interval (CI) 1.00-1.88, P = 0.050]. This association appeared to be more pronounced in patients with prostate cancer (OR 1.98, 95% CI 1.06-3.70, P = 0.030) and pancreatic cancer (OR 7.22, 95% CI 1.40-37.25, P = 0.020).
[CONCLUSIONS] While our findings indicate a possible association between PARPi and VTE risk in certain cancer types, this risk appears to be influenced by factors such as cancer subtype and treatment combinations. The overall contribution of PARPi monotherapy to VTE risk may be limited, and the results should be interpreted with caution due to study heterogeneity, wide CIs, and the absence of patient-level data.
🏷️ 키워드 / MeSH
같은 제1저자의 인용 많은 논문 (5)
- Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration-Sensitive Prostate Cancer.
- Less Can Be Enough: Optimizing Abiraterone Acetate Dosing With Food to Improve Access and Maintain Efficacy in Metastatic Castration-Resistant Prostate Cancer.
- Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical Trials.
- The prognostic value of elimination rate constant K score of prostate-specific antigen in metastatic castration-resistant prostate cancer patients treated with docetaxel.
- Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy.